Underlying data, code and supporting documentation for this paper are available at <https://datacompass.lshtm.ac.uk/1151/>. The full dataset cannot be made open access due to the presence of participant identifiable content. However, a redacted version will be provided to interested parties, subject to the completion of a request form (available via the repository link above) and signing of a Data Transfer Agreement.

Introduction {#sec008}
============

Malnutrition is a major global public health problem, contributing to the deaths of approximately 3 million children under age 5 years each year \[[@pmed.1003192.ref001]\]. Acute malnutrition affects more than 50 million children under age 5 and is particularly serious: As well as having a high short-term case fatality rate, it also has important long-term sequelae \[[@pmed.1003192.ref002]--[@pmed.1003192.ref005]\]. Tackling malnutrition is unfinished business from the Millennium Development Goals and remains prominent in the Sustainable Development Goals (SDGs). SDG 2.2 aims to "end all forms of malnutrition, including achieving by 2025 the internationally agreed targets on stunting and wasting in children under 5 years of age" \[[@pmed.1003192.ref006]\]. Despite its importance, there is increasing concern that current approaches to acute malnutrition are suboptimal \[[@pmed.1003192.ref007]--[@pmed.1003192.ref009]\]. Successful treatments are available, but treatment program coverage is low, with at least 75% of acutely malnourished children 6--59 months old not accessing care \[[@pmed.1003192.ref010],[@pmed.1003192.ref011]\]. This makes achieving impact at national and international levels difficult.

Acute malnutrition can be seen as a continuum condition, but current treatments for acute malnutrition are separated into 2 components: those treating severe acute malnutrition (SAM) and those treating moderate acute malnutrition (MAM). Children with SAM have the highest risks for morbidity and mortality, but children with MAM remain at risk for adverse outcomes including illness and death \[[@pmed.1003192.ref001],[@pmed.1003192.ref012]--[@pmed.1003192.ref016]\]. SAM is currently defined as weight-for-height \< −3 standard deviations (*z*-scores) below the WHO reference median and/or a mid-upper arm circumference (MUAC) \< 11.5 cm and/or edema; MAM is currently defined as weight-for-height from −3 to \<−2 standard deviations (*z*-scores) below the WHO reference median and/or a MUAC from 11.5 cm to \<12.5 cm.

SAM and MAM are managed in separate programs, using different food products and protocols. There is currently no globally accepted guidance for the treatment of MAM, and MAM is not always routinely treated \[[@pmed.1003192.ref017],[@pmed.1003192.ref018]\]. International mandate adds an additional layer of complexity: UNICEF supports the treatment of SAM and provides ready-to-use therapeutic food (RUTF) for use in outpatient therapeutic programs (OTPs); the World Food Programme supports the treatment of MAM and provides ready-to-use supplementary food (RUSF) or fortified blended flours for use in supplementary feeding programs (SFPs) \[[@pmed.1003192.ref019],[@pmed.1003192.ref020]\]. In humanitarian settings, providing treatment for both SAM and MAM adds to the logistical and financial burden of health systems. When resources are scarce, and in the many settings where prevalence is not high enough to reach emergency thresholds, treatment of SAM is often prioritized, and children with MAM may not be eligible to receive care unless they deteriorate.

The Combined Protocol for Acute Malnutrition Study (ComPAS) unified the treatment of uncomplicated SAM and MAM for children 6--59 months into one protocol, with simplified diagnostic criteria and a single therapeutic food product. This is the first randomized controlled trial we are aware of to test a simple, MUAC-based dosage protocol for the treatment of SAM and MAM in children 6--59 months. A clinical trial assessing the effectiveness of an integrated SAM/MAM approach using a weight-based dosage protocol found similar recovery and lower therapeutic food costs in the integrated treatment arm \[[@pmed.1003192.ref021]\]. An operational study of children admitted with a MUAC \< 12.5 cm and/or edema and treated with a gradually reduced dosage of RUTF based on a combination of MUAC status and weight also found a high overall recovery rate \[[@pmed.1003192.ref022]\]. Multiple studies assessing the use of MUAC in nutrition programs have shown that MUAC is effective at identifying children most at risk of mortality and is simpler and easier to use than weight-for-height measures \[[@pmed.1003192.ref023],[@pmed.1003192.ref024]\]. MUAC gain can be used as a proxy for weight gain \[[@pmed.1003192.ref025]--[@pmed.1003192.ref028]\], and rate of weight and MUAC gain in response to treatment appears to decline as children recover \[[@pmed.1003192.ref025],[@pmed.1003192.ref026],[@pmed.1003192.ref028],[@pmed.1003192.ref029]\]. Current standard of care provides a weight-based dosage of up to 200 kcal/kg/day for all children with SAM ([S1 Table](#pmed.1003192.s007){ref-type="supplementary-material"}), but this dosage is based on the rate of weight gain in inpatient settings, which is higher than in outpatient settings \[[@pmed.1003192.ref029]\]. Several recent studies of children with SAM in outpatient settings indicate that recovery with a reduced dosage is similar to recovery with standard treatment \[[@pmed.1003192.ref021],[@pmed.1003192.ref022],[@pmed.1003192.ref030],[@pmed.1003192.ref031]\]. A study of children treated for SAM in Myanmar reduced the dosage to 500 kcal/day of RUTF once children reached a MUAC of 11.0 cm and a weight-for-height *z-*score (WHZ) ≥ −3 and achieved recovery above Sphere standards \[[@pmed.1003192.ref030]\]. A study in Burkina Faso found that a reduced dosage of RUTF offered to SAM patients beginning in the third week of treatment resulted in non-inferior weight gain velocity and similar recovery and length of stay, though height gain velocity was reduced \[[@pmed.1003192.ref031]\]. As children recover from SAM to MAM, current global practice reduces the dosage of energy received to provide a supplement rather than a replacement for the family diet, typically offering 1 sachet of RUSF per day (500--550 kcal/day) \[[@pmed.1003192.ref018],[@pmed.1003192.ref032]\]. We previously conducted a secondary analysis of program data from 5 countries and found that children recovering from acute malnutrition with a MUAC \< 12.5 cm may require 1,000 kcal per day, a reduced dosage compared to standard care \[[@pmed.1003192.ref025]\]. The rationale for a reduced dosage is to facilitate increased coverage---and in turn increased public health impact---of treatment in a resource-constrained environment. The optimal dosage achieves the right balance between meeting individual energy needs and extending treatment to more children. This study contributes to the evidence on the impact of different dosage regimes.

This study aimed to test the hypothesis that the combined protocol would be non-inferior to the standard protocol in terms of recovery, and improve cost-effectiveness.

Methods {#sec009}
=======

Study design {#sec010}
------------

ComPAS was a cluster-randomized non-inferiority trial conducted in 24 health facilities in Nairobi, Kenya, and Aweil East, South Sudan. We selected a cluster-randomized design in order to ensure fidelity to the assigned protocol at the health facility level, and to improve disaggregation of cost data by protocol type. We tested for non-inferiority, assuming recovery under the simplified protocol would be at least as good as under standard care. The clinical trial described in this paper builds on analysis conducted by our team to develop a simplified, combined protocol \[[@pmed.1003192.ref025]\]. We previously published a full description of the protocol for this trial, as well as the methods for the cost-effectiveness analyses \[[@pmed.1003192.ref033],[@pmed.1003192.ref034]\]. Ethical approval was given by the London School of Hygiene & Tropical Medicine (reference 11826), the Kenya Medical Research Institute (reference non-KEMRI 551), and the Ministry of Health in South Sudan (approved 21 November 2016).

Participants {#sec011}
------------

Aweil East, South Sudan, is a rural, agro-pastoralist region in Northern Bahr el Ghazal State with a total population of 309,921 and an under 5 population of 59,574 \[[@pmed.1003192.ref035]\]. Nairobi, Kenya, is an urban area with a total population of 3,078,108 and an under 5 population of 462,849 \[[@pmed.1003192.ref036]\]. Three sub-counties of Nairobi were included in the study: Embakasi North, Embakasi East, and Embakasi West.

Health facilities were eligible for selection as clusters. Only 12 health facilities were operating nongovernmental organization (NGO)--supported nutrition services in Aweil East at the time of randomization, and all were selected for participation. In Nairobi, the Ministry of Health aided selection of 12 health facilities in 3 sub-counties with the highest burden of malnutrition. Of the 32 health facilities in the 3 sub-counties of Nairobi, clinics were selected based on the following factors: the level of care provided (hospitals and dispensaries excluded), the type of care provided (routine child health services available), the population served (slum or peri-urban communities), and expected caseload of malnutrition. Children aged 6--59 months presenting to any of the 24 clinics involved in the study were eligible to enroll ([S2 Table](#pmed.1003192.s008){ref-type="supplementary-material"}). Active case finding was also conducted by community health workers using MUAC to find and refer children. Active case finding was conducted in the same way for all clinics across both treatment arms and countries. Children admitted with a MUAC \< 12.5 cm and/or edema (+/++, i.e., mild or moderate) were eligible for inclusion. Children exhibiting signs of a severe illness or danger sign according to the Integrated Management of Childhood Illness (IMCI) algorithm, or not passing the appetite test (consumption of 30 g of RUTF within 20 minutes), were excluded and referred for further assessment and care at an inpatient stabilization center or hospital \[[@pmed.1003192.ref033],[@pmed.1003192.ref037]\].

Clinic-level and individual consent were obtained. Local health authorities and clinic managers gave written permission for their clinics to be included prior to randomization. For individual caretakers of malnourished children, participation was first explained in their local language (Dinka in South Sudan; Kiswahili or English in Nairobi). Caretakers were provided with an information sheet describing details of the interventions, and staff emphasized that treatment would be available to all regardless of whether they chose to participate. A consent document was signed by caretakers, or by a witness who could attest to the caretaker's verbal consent.

Randomization and blinding {#sec012}
--------------------------

The 24 health clinics were indexed and sent to the senior statistician (CO) based in London, who did not have any prior knowledge of their identities or characteristics. The statistician generated a randomized sequence list stratified by country using the Sealed Envelope randomized sequence generator and applied it to the list of the health facilities \[[@pmed.1003192.ref038]\]. Participants were enrolled in the study arm of the clinic they presented to, by the research officer based at each clinic. Given that the intervention was applied at the facility level, clinic staff could not be blinded to group allocation, and neither could participants. To ensure objective trial management, the principal investigator (JB) was blinded to clinic allocation and outcomes by treatment arm until the last participant exited the trial and the database was locked. For data monitoring purposes during the trial, a data manager sent de-identified data to the PI, with site codes replacing clinic names and all information identifying clinics or treatment arms removed. The senior statistician revealed clinic allocation only after the trial database had been closed \[[@pmed.1003192.ref033]\].

Study procedures {#sec013}
----------------

In standard protocol clinics, children with SAM received RUTF according to weight (200 kcal/kg/day) in the OTP ([S2 Table](#pmed.1003192.s008){ref-type="supplementary-material"}). Children with MAM received 500 kcal/day of RUSF (1 sachet/day) in the SFP. The OTPs and SFPs in the control arm in both countries operated from the same clinics with the same staff. In combined protocol clinics, children with a MUAC \< 11.5 cm and/or edema (+/++) received 1,000 kcal RUTF/day (2 sachets/day), and children with a MUAC of 11.5 to \<12.5 cm and no edema received 500 kcal RUTF/day (1 sachet/day). When children met the criteria for transition from SAM to MAM (MUAC ≥ 11.5 cm and no edema for 2 consecutive visits), they were switched from 2 sachets of RUTF/day to 1 sachet of RUTF/day. This reduction in dosage is based on the slowing rate of growth that we observed at a MUAC of approximately 11.5 cm in our stage 1 study \[[@pmed.1003192.ref025]\] and aligns with UN guidance on the treatment of MAM \[[@pmed.1003192.ref018],[@pmed.1003192.ref032]\]. Children in the combined protocol arm were registered as either an OTP or SFP patient based on their admission MUAC.

In the standard protocol, children were only included in this analysis if their MUAC on admission was \<12.5 cm and/or they had edema (+/++). If they also met the WHZ \< −2 criterion on admission and reached WHZ ≥ −2 prior to reaching MUAC ≥ 12.5 cm during treatment, they were not discharged until they had a MUAC measurement of ≥12.5 cm for 2 consecutive visits, to ensure parity of the definition of recovery between the intervention and control arms.

In both arms, children with SAM came once a week for a medical and nutritional evaluation and received systematic medications per the national protocol. Children with MAM attended every 2 weeks and received only a nutritional consultation, unless they required medical attention. Children who were found not to be gaining adequate weight or not progressing towards recovery (non-responders) were referred for medical assessment and/or inpatient care. Defaulters were traced by community health workers and referred to care if they were found to still be malnourished (though they were not re-enrolled in the study). All non-nutritional components of treatment such as systematic medications, frequency of follow-up, and home visits to prevent defaulting were identical between the combined and standard protocol arms. Full details of the combined and standard protocols were previously published \[[@pmed.1003192.ref033]\] and are summarized in [S2 Table](#pmed.1003192.s008){ref-type="supplementary-material"}.

Outcomes {#sec014}
--------

The primary outcome was recovery in the per-protocol analysis, defined as reaching a MUAC measurement of ≥12.5 cm and no edema for 2 consecutive visits (weekly for SAM and biweekly for MAM). Secondary outcomes included cost-effectiveness, death (including post-defaulting deaths confirmed during defaulter tracing and follow-up phone calls when possible), non-response (16 weeks in treatment without achieving recovery), transfer (to either a stabilization center or a different facility), and defaulting (3 consecutive missed visits). The outcome categories recovery, death, non-response, defaulting, and transfer were mutually exclusive. To account for MAM children attending visits biweekly, we extended the non-response cutoff for all children to 17 weeks to evaluate the status of MAM children who would not have come for a visit at 16 weeks. Clinic staff determined whether children had met specified criteria in the protocol and discharged them from further follow-up. The criteria for each outcome (e.g., recovery being defined by 2 consecutive visits with a MUAC ≥ 12.5 cm and no edema) were prespecified in the study protocol, and outcomes were assigned according to the strict definitions described in the study protocol. This process ensured that any discharge errors by clinic staff would be identified and accounted for during the analysis. An additional outcome category of early discharge was added during the analysis phase to account for children mistakenly discharged by the clinic staff before their outcome could be ascertained. The providers in each of the clinics were given on-site practical trainings in anthropometry and refresher trainings. Details of the procedures for taking anthropometric measurements are available in [S1 Text](#pmed.1003192.s012){ref-type="supplementary-material"}. Research officers (registered nutritionists and supervisors for clinic staff) oversaw and repeated measurements to ensure agreement with clinic staff. Analyses of length of stay, average daily weight gain (g/kg/day), and average daily MUAC gain (mm/day) were conducted on children who achieved recovery. All outcomes were measured at the individual level. A formal data and safety monitoring board was not planned due to the expected short duration of recruitment. Instead, a trial safety committee comprising an independent chair and a statistician conducted a safety review at the midpoint of the trial. Outcomes and adverse events, including hospitalizations and deaths, were reported to the safety committee at the midpoint of recruitment. The committee, upon reviewing the safety report, recommended continuation of recruitment with no amendments to the protocol \[[@pmed.1003192.ref033]\].

To assess cost-effectiveness, we calculated costs from a societal perspective, using accounting data, interviews with key informants, and survey questionnaires given to a subset of staff and all caregivers. Details have been described in our cost analysis methods paper \[[@pmed.1003192.ref034]\]. We categorized costs into treatment, outreach, supply logistics, supervision, management, and household costs for each country.

We used a modified version of the Semi-Quantitative Evaluation of Access and Coverage (SQUEAC) assessment to assess coverage \[[@pmed.1003192.ref039]\]. The SQUEAC method uses Bayesian techniques with a small sample survey to produce single coverage estimates. The coverage surveys assessed only MUAC and edema, in keeping with the study definitions of SAM and MAM. Coverage estimates are presented for SAM (MUAC \< 11.5 and/or edema) and MAM (MUAC 11.5 to \<12.5 cm) in each country and for each arm.

Statistical analysis {#sec015}
--------------------

Our sample size was designed to detect non-inferiority of recovery for the combined protocol compared to the standard protocol in the per-protocol analysis with a 10% non-inferiority margin and 80% power at a 2-sided level of significance of 5%. Based on these parameters, 12 clusters per arm were required, with 100 children in each cluster. The 10% non-inferiority margin was selected based on previous program data reporting a recovery rate of 85%, with a minimum acceptable recovery rate of 75% per Sphere standards \[[@pmed.1003192.ref040]\]. An intra-cluster correlation coefficient of 0.05 was assumed, based on results of a similar trial \[[@pmed.1003192.ref021]\]. An additional adjustment to the sample size calculation was made to anticipate losses to follow-up and crossovers (children who are cross-registered across arms and need to be excluded during the analysis), in order to determine how many children should be recruited per cluster to ensure 100 children with completed treatment for the per-protocol analysis. Thus, the sample size was calculated to recruit enough children per cluster so that when defaulters (and other non-adherents, such as transfers or early discharges) were removed from the denominator, the power of the study would be maintained. Losses to follow-up were expected to be 15%, based on Sphere standards, and crossovers were expected to be 5%, so we aimed to recruit 150 children per cluster to achieve our target of 100 per cluster for the per-protocol analysis \[[@pmed.1003192.ref033],[@pmed.1003192.ref041],[@pmed.1003192.ref042]\].

We used CommCare for data management \[[@pmed.1003192.ref043]\]. In Kenya, clinic-based research officers entered data on Samsung Galaxy Tab A tablets running Android OS v.5.1.1 and uploaded data to the CommCare server. In South Sudan, nutrition supervisors initially collected data on paper forms. Data were then entered by 2 data entry clerks into Samsung Galaxy Tab A tablets running Android OS v.4.4 and uploaded to the CommCare server. Data entry onto paper forms and tablets was supervised and cross-checked by field coordinators. Data entry errors were logged and checked by the field coordinators and the principal investigator before incorporation into the database \[[@pmed.1003192.ref033]\].

We conducted both per-protocol and intention-to-treat analyses. We designed this trial with per-protocol as the main analysis because it is more conservative and is the recommended approach for primary analysis of non-inferiority trials \[[@pmed.1003192.ref033],[@pmed.1003192.ref044],[@pmed.1003192.ref045]\]. Non-inferiority was assessed only for the primary outcome of recovery. For secondary outcomes we explored evidence of a difference, rather than non-inferiority. The intention-to-treat analysis included all children enrolled, and the per-protocol analysis excluded children who did not complete treatment: those who exited the study as transfers to other facilities, defaulters lost to follow-up, or early discharges from treatment. Non-inferiority of the primary outcome of recovery was defined as a difference in proportion of children recovering from acute malnutrition with the upper bound of the 95% confidence interval being less than 10%. We used binomial regression models for binary outcomes and linear regression models for continuous outcomes. In both approaches we used clustered robust standard errors to adjust for repeated measures (clustering) within health facilities. We adjusted for the baseline characteristics of age, sex, and country in all the adjusted analyses. For costs with the greatest uncertainty we conducted a univariate sensitivity analysis. We present a mean base-case value across both countries, in US dollars, for cost per child treated, cost per child recovered, and the incremental cost of implementing the combined protocol compared to standard treatment. Analysis was conducted using Stata/IC v.13.1 \[[@pmed.1003192.ref046]\]. Stata's zscore06 package was used to calculate WHZ, height-for-age *z*-score, and weight-for-age *z*-score (according to WHO Child Growth Standards) and flags \[[@pmed.1003192.ref047]\].

The trial is registered at ISRCTN: trial number ISRCTN30393230 (<http://www.isrctn.com/ISRCTN30393230>). This study is reported according to the Consolidated Standards of Reporting Trials (CONSORT) guidelines ([S3 Text](#pmed.1003192.s014){ref-type="supplementary-material"}; [S4 Text](#pmed.1003192.s015){ref-type="supplementary-material"}).

Results {#sec016}
=======

Recruitment began 8 May 2017 and ended 31 March 2018. Trial activities were completed in Kenya on 31 July 2018 and in South Sudan on 31 August 2018, when the last enrolled children completed treatment. Among the children attending nutrition services at the participating health clinics, 157 children had WHZ \< −2 but did not meet eligibility criteria because they had a MUAC ≥ 12.5 cm and no edema; these children were enrolled in a sub-study and their outcomes will be presented in a forthcoming paper. A total of 4,110 children met eligibility criteria and were enrolled ([Fig 1](#pmed.1003192.g001){ref-type="fig"}). Of these, 30 were excluded from analysis due to a missing admission date. Two more were excluded due to implausible MUAC values. The intention-to-treat analysis included 24 clusters and 4,078 children. After removing those who did not complete treatment, the per-protocol analysis included 24 clusters and 2,488 children ([Fig 1](#pmed.1003192.g001){ref-type="fig"}). The target per-protocol sample size of 100 children per cluster was met: In the combined protocol arm the median sample per cluster was 107.5 (IQR 99.5--118); in the standard protocol arm the median sample per cluster was 102.4 (IQR 97--107.5).

![Trial profile.\
MAM, moderate acute malnutrition; MUAC, mid-upper arm circumference; SAM, severe acute malnutrition.](pmed.1003192.g001){#pmed.1003192.g001}

Baseline characteristics were similar in the 2 study arms ([Table 1](#pmed.1003192.t001){ref-type="table"}). There were more females than males in the sample, and children had a mean age of around 17 months. About three- quarters of the children were aged between 6 and 24 months. Baseline characteristics by country are shown in [S3 Table](#pmed.1003192.s009){ref-type="supplementary-material"}. Inter-country differences include the following: children in South Sudan were on average older than in Kenya (mean 22 versus 12 months); the Sudanese population was more rural, with household income mainly from fishing and farming; the Kenyan setting was more urban, with most household income from shopkeeping, casual labor, and salaried work; maternal education level in South Sudan was low, whereas most mothers in Kenya reported secondary level education ([S3 Table](#pmed.1003192.s009){ref-type="supplementary-material"}).

10.1371/journal.pmed.1003192.t001

###### Admission characteristics of children in the combined and standard protocols.

![](pmed.1003192.t001){#pmed.1003192.t001g}

  Characteristic                                                                                             Combined protocol (*N* = 12, *n* = 2,071)   Standard protocol (*N* = 12, *n* = 2,039)
  ---------------------------------------------------------------------------------------------------------- ------------------------------------------- -------------------------------------------
  **Sex and age**                                                                                                                                        
  Male, *n* (%)                                                                                              841 (41%)                                   841 (41%)
  Age in months, mean (SD)                                                                                   17.4 (11.4)                                 16.7 (10.7)
  Age category, *n* (%)                                                                                                                                  
      6 to \<24 months                                                                                       1,502 (73%)                                 1,542 (76%)
      ≥24 months                                                                                             564 (27%)                                   495 (24%)
  **Anthropometrics**                                                                                                                                    
  Weight (kg), mean (SD)                                                                                     7.2 (1.6)                                   7.3 (1.6)
  Height (cm)[^a^](#t001fn002){ref-type="table-fn"}, mean (SD)                                               72.9 (8.9)                                  73.0 (8.7)
  MUAC (cm), mean (SD)                                                                                       11.7 (.55)                                  11.7 (.59)
  WHZ, mean (SD)                                                                                             −2.5 (1.0)                                  −2.3 (3.4)
  HAZ, mean (SD)                                                                                             −2.1 (1.6)                                  −1.9 (1.6)
  WAZ, mean (SD)                                                                                             −2.9 (1.0)                                  −2.7 (1.1)
  MUAC \< 11.5 cm, *n* (%)                                                                                   601 (29%)                                   634 (31%)
      WHZ \< −3                                                                                              352 (59%)                                   346 (55%)
      WHZ ≥ −3 to \<−2                                                                                       189 (32%)                                   208 (33%)
      WHZ ≥ −2                                                                                               60 (10.0%)                                  80 (12.6%)
  MUAC 11.5 to \<12.5 cm, *n* (%)                                                                            1,461 (71%)                                 1,397 (69%)
      WHZ \< −3                                                                                              258 (18%)                                   158 (11%)
      WHZ ≥ −3 to \<−2                                                                                       650 (45%)                                   550 (39%)
      WHZ ≥ −2                                                                                               553 (38%)                                   689 (49%)
  Edema (+ or ++), *n* (%)                                                                                   23 (1%)                                     24 (1%)
  **Other participant characteristics**                                                                                                                  
  Child breastfed in last 24 hours, *n* (%)                                                                  1,437 (69%)                                 1,426 (70%)
  Caretaker reports any morbidity[^b^](#t001fn003){ref-type="table-fn"} in child in past week, *n* (%)       1,320 (64%)                                 1,179 (58%)
      Fever                                                                                                  787 (38%)                                   714 (35%)
      Diarrhea                                                                                               521 (25%)                                   517 (25%)
      Cough                                                                                                  651 (31%)                                   694 (34%)
  Health care sought in prior week                                                                           489 (24%)                                   339 (20%)
  HIV status, *n* (%)                                                                                                                                    
      Positive                                                                                               9 (0%)                                      5 (0%)
      Exposed (mother)                                                                                       19 (1%)                                     17 (1%)
  Disabled (physically or mentally)                                                                          44 (2%)                                     38 (2%)
  Tuberculosis (+), *n* (%)                                                                                  6 (0%)                                      3 (0%)
  **Household characteristics**                                                                                                                          
  Mother is caretaker, *n* (%)                                                                               1,978 (96%)                                 1,923 (94%)
  Maternal educational achievement, *n* (%)                                                                                                              
      None                                                                                                   927 (47%)                                   837 (44%)
      Pre-primary                                                                                            9 (1%)                                      13 (1%)
      Primary                                                                                                475 (24%)                                   485 (25%)
      Secondary                                                                                              566 (29%)                                   585 (30%)
      College tertiary                                                                                       0 (0%)                                      1 (0%)
  Number of children under 5 years in the home, mean (SD)                                                    1.5 (1.0)                                   1.7 (0.8)
  Access to toilet, *n* (%)                                                                                  1,314 (64%)                                 1,342 (66%)
  Water source, *n* (%)                                                                                                                                  
      Household tap                                                                                          92 (4%)                                     174 (9%)
      Community tap/tap stand                                                                                684 (33%)                                   742 (36%)
      Hand pump/borehole                                                                                     746 (36%)                                   518 (25%)
      Borehole (private)                                                                                     162 (8%)                                    452 (22%)
      Vendors                                                                                                227 (11%)                                   77 (4%)
      Open water                                                                                             152 (7%)                                    67 (3%)
  Livelihood/main source of income, *n* (%)                                                                                                              
      No income                                                                                              10 (1%)                                     112 (6%)
      Sale of items (grass, firewood, livestock)                                                             324 (16%)                                   97 (5%)
      Fishing/farming                                                                                        649 (31%)                                   559 (27%)
      Business/shopkeeper                                                                                    226 (11%)                                   586 (29%)
      Casual labor                                                                                           529 (26%)                                   586 (29%)
      Salaried work                                                                                          301 (15%)                                   284 (14%)
      Other                                                                                                  21 (1%)                                     29 (1%)
  Ever no food to eat^c^, *n* (%)                                                                                                                        
      Never                                                                                                  1,022 (49%)                                 1,294 (64%)
      Rarely                                                                                                 550 (27%)                                   380 (19%)
      Sometimes                                                                                              407 (20%)                                   309 (15%)
      Often                                                                                                  73 (4%)                                     43 (2%)
      Don't know                                                                                             2 (0%)                                      7 (0%)
  Ever go to sleep without enough food^c^, *n* (%)                                                                                                       
      Never                                                                                                  1,205 (50%)                                 1,189 (58%)
      Rarely                                                                                                 543 (26%)                                   490 (24%)
      Sometimes                                                                                              454 (22%)                                   291 (14%)
      Often                                                                                                  39 (2%)                                     43 (2%)
      Don't know                                                                                             2 (0%)                                      20 (1%)
  Any household member go whole day without eating anything[^c^](#t001fn004){ref-type="table-fn"}, *n* (%)                                               
      Never                                                                                                  1,097 (53%)                                 1,238 (61%)
      Rarely                                                                                                 507 (25%)                                   438 (22%)
      Sometimes                                                                                              421 (20%)                                   279 (14%)
      Often                                                                                                  37 (2%)                                     43 (2%)
      Don't know                                                                                             1 (0%)                                      35 (2%)

*N* = number of clusters; *n* = individual children eligible for treatment.

^a^Recumbent length was taken for children 6--23 months, and standing height was taken for children 24 months and older.

^b^"Any morbidity" includes diarrhea, fever, cough, vomiting, skin infection, and other illness.

^c^From Household Hunger Scale.

HAZ, height-for-age *z-*score; MUAC, mid-upper arm circumference; WAZ, weight-for-age *z-*score; WHZ, weight-for-height *z-*score.

In the per-protocol analysis, children in the combined protocol arm had non-inferior recovery (76.3% in the combined arm versus 73.5% in the standard arm; adjusted risk difference 0.03, 95% CI −0.05 to 0.10, *p =* 0.52) ([Table 2](#pmed.1003192.t002){ref-type="table"}; [Fig 2](#pmed.1003192.g002){ref-type="fig"}). There was no evidence of a difference in the secondary outcomes death (1.8% versus 1.8%; adjusted risk difference 0.00, 95% CI −0.01 to 0.01, *p =* 0.87) and non-response (21.9% versus 24.7%; adjusted risk difference −0.03, 95% CI −0.10 to 0.05, *p =* 0.48). Results in the intention-to-treat analysis were similar, with non-inferior recovery in the combined protocol (47.6% in the combined arm versus 43.8% in the standard arm; adjusted risk difference 0.03, 95% CI −0.06 to 0.13, *p =* 0.47) ([Table 2](#pmed.1003192.t002){ref-type="table"}; [Fig 2](#pmed.1003192.g002){ref-type="fig"}). There was no evidence of a difference between arms in the risk of the secondary outcomes death (1.1% versus 1.0%; adjusted risk difference 0.00, 95% CI −0.01 to 0.01, *p =* 0.79), non-response (13.7% versus 14.7%; adjusted risk difference −0.01, 95% CI −0.05 to 0.04, *p =* 0.73); defaulting (24.7% versus 30.7%; adjusted risk difference −0.06, 95% CI −0.15 to 0.03, *p =* 0.20), and transfer to inpatient care (1.7% versus 1.1%; adjusted risk difference 0.01, 95% CI −0.01 to 0.02, *p =* 0.42) ([Table 2](#pmed.1003192.t002){ref-type="table"}). The intra-cluster correlation coefficient for recovery was 0.05 (95% CI 0.01 to 0.08) for the per-protocol analysis and 0.06 (95% CI 0.02 to 0.09) for the intention-to-treat analysis.

![Per-protocol (PP) and intention-to-treat (ITT) analyses of recovery.](pmed.1003192.g002){#pmed.1003192.g002}

10.1371/journal.pmed.1003192.t002

###### Primary and secondary outcomes (per-protocol and intention-to-treat analyses).

![](pmed.1003192.t002){#pmed.1003192.t002g}

  Outcome                                                          Standard protocol   Combined protocol   Unadjusted   Adjusted                                                          
  ---------------------------------------------------------------- ------------------- ------------------- ------------ ---------- ----------------------- ------ ----------------------- ------
  ***Per-protocol***[^a^](#t002fn003){ref-type="table-fn"}                                                                                                                                
  **Primary outcome**                                                                                                                                                                     
  Recovery                                                         884                 73.5%               981          76.3%      0.03 (−0.06 to 0.11)    0.52   0.03 (−0.05 −0.10)      0.52
  **Secondary outcomes**                                                                                                                                                                  
  Death                                                            21                  1.8%                23           1.8%       0.00 (−0.01 to 0.01)    0.95   0.00 (−0.01 to 0.01)    0.87
  Non-response                                                     297                 24.7%               282          21.9%      −0.03 (−0.11 to 0.05)   0.49   −0.03 (−0.10 to 0.05)   0.48
  ***Intention-to-treat***[^b^](#t002fn004){ref-type="table-fn"}                                                                                                                          
  **Primary outcome**                                                                                                                                                                     
  Recovery                                                         884                 43.8%               981          47.6%      0.04 (−0.06 to 0.14)    0.46   0.03 (−0.06 to 0.13)    0.47
  **Secondary outcomes**                                                                                                                                                                  
  Death                                                            21                  1.0%                23           1.1%       0.00 (−0.01 to 0.01)    0.84   0.00 (−0.01 to 0.01)    0.79
  Non-response                                                     297                 14.7%               282          13.7%      −0.01 (−0.06 to 0.04)   0.66   −0.01 (−0.05 to 0.04)   0.73
  Defaulting                                                       619                 30.7%               508          24.7%      −0.06 (−0.15 to 0.03)   0.20   −0.06 (−0.15 to 0.03)   0.20
  Transfer                                                         51                  2.5%                77           3.7%       0.01 (−0.01 to 0.04)    0.38   0.01 (−0.01 to 0.03)    0.17
      Inpatient                                                    23                  1.1%                35           1.7%       0.01 (−0.01 to 0.02)    0.51   0.01 (−0.01 to 0.02)    0.42
      New facility                                                 28                  1.4%                42           2.0%       0.01 (−0.01 to 0.02)    0.44   0.01 (−0.01 to 0.02)    0.30
  Early discharge                                                  145                 7.2%                190          9.2%       0.02 (−0.04 to 0.08)    0.53   0.02 (−0.02 to 0.06)    0.36

Unadjusted: all children with outcome measures, not adjusted for any demographic or study design characteristics. Adjusted: adjusted for age, sex, and country. *N* = number of clusters; *n* = number of children eligible for follow-up.

^§^Standard errors adjusted for clustering within facilities.

^a^Standard protocol: *N* = 12, *n* = 1,202; combined protocol: *N* = 12, *n* = 1,286.

^b^Standard protocol: *N* = 12, *n* = 2,017; combined protocol: *N* = 12, *n* = 2,061.

Among children who recovered, there was no evidence of a difference between the combined and standard protocols in length of stay (65.4 versus 65.0 days; adjusted mean difference −0.55, 95% CI −5.75 to 4.65, *p =* 0.83), average daily weight gain (1.9 versus 1.9 g/kg/day; adjusted mean difference 0.08, 95% CI −0.13 to 0.29, *p =* 0.42), and average daily MUAC gain (0.2 versus 0.2 mm/day; adjusted mean difference −0.01, 95% CI −0.04 to 0.02, *p =* 0.45) ([Table 3](#pmed.1003192.t003){ref-type="table"}).

10.1371/journal.pmed.1003192.t003

###### Secondary outcomes among recovered children.
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  Outcome                                Standard protocol (*N* = 12, *n* = 884)   Combined protocol (*N* = 12, *n* = 981)   Unadjusted   Adjusted                                                          
  -------------------------------------- ----------------------------------------- ----------------------------------------- ------------ ---------- ----------------------- ------ ----------------------- ------
  Length of stay (days)                  65.0                                      2.31                                      65.4         2.24       0.42 (−6.19 to 7.04)    0.90   −0.55 (−5.75 to 4.65)   0.83
  Average daily weight gain (g/kg/day)   1.9                                       0.08                                      1.9          0.08       0.06 (−0.17 to 0.29)    0.61   0.08 (−0.13 to 0.29)    0.42
  Average daily MUAC gain (mm/day)       0.2                                       0.01                                      0.2          0.01       −0.01 (−0.05 to 0.02)   0.39   −0.01 (−0.04 to 0.02)   0.45

Unadjusted: all children with outcome measures, not adjusted for any demographic or study design characteristics. Adjusted: adjusted for age, sex, and country. *N* = number of clusters; *n* = number of children eligible for follow-up.

MUAC, mid-upper arm circumference.

Coverage results were similar for both protocols, with overlapping confidence intervals for all results. In Kenya, the coverage for SAM (MUAC \< 11.5 cm and/or edema) was estimated at 54.9% (95% CI 41.2% to 68.0%) and 52.9% (95% CI 39.1% to 66.2%) for the combined and standard protocol arms, respectively. For MAM (MUAC 11.5 to \<12.5 cm), coverage was 48.6% (95% CI 38.0% to 59.4%) and 47.3% (95% CI 37.1% to 58.0%) for the combined and standard protocol arms, respectively. In South Sudan, coverage for SAM was estimated at 45.9% (95% CI 32.5% to 59.9%) and 62.5% (95% CI 47.8% to 75%) for the combined and standard protocol arms, respectively. For MAM, coverage was 21.3% (95% CI 14.9% to 29.2%) and 26.3% (95% CI 19.2% to 35.1%) for the combined and standard protocol arms, respectively ([S4 Table](#pmed.1003192.s010){ref-type="supplementary-material"}).

Kaplan--Meier plots showing the time to recovery are presented in [S1](#pmed.1003192.s001){ref-type="supplementary-material"}--[S6](#pmed.1003192.s006){ref-type="supplementary-material"} Figs. Median time to recovery in the per-protocol analysis was approximately 10 weeks, with similar time to recovery in both arms.

Data from research grant accounts, NGO operational accounts, 83 key informant interviews, and 64 caregiver interviews were used to compute the total economic costs per treatment arm and country ([Table 4](#pmed.1003192.t004){ref-type="table"}). To reach recovery in Kenya, SAM children in the standard protocol arm received on average 148 sachets of ready-to-use food (RUTF and RUSF), and SAM children in the combined protocol arm received on average 105 sachets of RUTF. To reach recovery in South Sudan, SAM children in the standard protocol arm received on average 209 sachets of RUTF and RUSF, and SAM children in the combined protocol arm received on average 133 sachets of RUTF. Overall, the average amount of ready-to-use food required for a child with SAM to reach full recovery (MUAC ≥ 12.5 cm and no edema for 2 consecutive visits) was lower in the combined protocol arm than in the standard protocol arm (122 versus 193 sachets). Combining mean costs and recovery rates across countries, per the statistical power of the study, the combined protocol costs US\$123 less per child recovered than the standard protocol ([Table 5](#pmed.1003192.t005){ref-type="table"}). The input costs partially include the added costs of running a research trial, as these could not be fully separated from treatment program costs.

10.1371/journal.pmed.1003192.t004

###### Input costs by country setting and treatment arm.
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  Cost category                  Input costs---South Sudan   Input costs---Kenya               
  ------------------------------ --------------------------- --------------------- ----------- -----------
  Treatment (includes product)   \$237,887                   \$243,991             \$176,251   \$174,164
  Product only                   \$34,863                    \$40,967              \$22,897    \$20,196
      SAM                        \$15,132                    \$26,492              \$6,576     \$6,678
      MAM                        \$19,731                    \$14,474              \$16,321    \$13,518
  Outreach                       \$71,329                    \$71,329              \$20,766    \$20,766
  Supply logistics               \$57,640                    \$69,220              \$30,756    \$30,756
  Supervision                    \$128,917                   \$128,917             \$14,125    \$15,919
  Management                     \$101,346                   \$101,346             \$41,397    \$41,397
  Household                      \$8,861                     \$9,891               \$11,563    \$11,680
  **Total**                      \$605,979                   \$624,692             \$294,859   \$294,683

All values in US dollars.

MAM, moderate acute malnutrition; SAM, severe acute malnutrition.

10.1371/journal.pmed.1003192.t005

###### Base-case cost-effectiveness results of the combined versus standard protocol.
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  Outcome                                               Combined protocol   Standard protocol
  ----------------------------------------------------- ------------------- -------------------
  Total cost (US dollars)                               \$900,838           \$919,376
  Number of children in program                         2,071               2,039
  Recovery rate (intention-to-treat)                    48%                 44%
  Number of children recovered                          981                 884
  Cost per child treated (US dollars)                   \$435               \$451
  Cost per child recovered (US dollars)                 \$918               \$1,041
  Incremental cost (total) (US dollars)                 −\$18,538           Ref
  Incremental cost (per child recovered) (US dollars)   −\$123              Ref

ITT, intention-to-treat; USD, US dollars.

Among the 1,127 children who defaulted, 1,103 (97.9%) were followed up with home visits. Of these, only 386 (35.0%) were home at the time of the defaulter tracing visit and had their status verified. Among children traced with status verified, 157 (69.2%) in the standard protocol arm and 83 (52.2%) in the combined protocol arm were found to be still malnourished (with a MUAC \< 12.5 cm and/or edema), 63 (27.8%) in the standard protocol arm and 72 (45.3%) in the combined protocol arm had recovered, 6 (2.6%) in the standard protocol arm and 2 (1.3%) in the combined protocol arm had died, and 1 (0.4%) in the standard protocol arm and 2 (1.3%) in the combined protocol arm were unknown. Among children with SAM, 284/641 (44.3%) defaulted in the standard protocol arm, and 209/617 (33.8%) defaulted in the combined protocol arm. Among children with MAM, 348/1,376 (25.3%) defaulted in the standard protocol arm and 308/1,444 (21.3%) defaulted in the combined protocol arm.

In exploratory analyses of sub-groups, children with SAM, children with MAM, children aged \<24 months, children aged ≥24 months, SAM children weighing ≥8 kg, children with a MUAC 11.5 to \<12.5 cm but WHZ \< −3, children in Kenya, and children in South Sudan recovered similarly under the combined protocol compared to the standard protocol ([S5 Table](#pmed.1003192.s011){ref-type="supplementary-material"}).

Discussion {#sec017}
==========

ComPAS compared a simplified, combined protocol for acute malnutrition to standard care, and found non-inferior nutritional recovery in the combined protocol arm relative to the standard care arm. The findings of the per-protocol and intention-to-treat analyses were similar. Clinical effectiveness was similar, with no evidence of a difference for the secondary outcomes death, non-response, defaulting, transfer to inpatient care, length of stay, program coverage, average daily weight gain, and average daily MUAC gain. Outcomes were similar between the study arms in exploratory analyses of sub-groups, including when disaggregated by SAM or MAM, and by country. The combined protocol cost less per child recovered than the standard protocol, especially for treatment of children with SAM and in the South Sudan context.

This study contributes evidence on integrated SAM/MAM treatment protocols, MUAC-based programming, and novel dosage regimes, which carry certain programmatic benefits: simplicity, ease of use, and potential cost-effectiveness. The combined protocol tested in this trial was the first to our knowledge to use a simple, MUAC-based dosage. Our findings are consistent with previous studies on integrated management of SAM and MAM with novel dosage regimes: a clinical trial in Sierra Leone that used a weight-based dosage protocol, with similar recovery and lower therapeutic food costs in the intervention arm of the study \[[@pmed.1003192.ref021]\], and an operational trial in Burkina Faso that achieved recovery above Sphere standards and used less therapeutic food than standard programs \[[@pmed.1003192.ref022]\].

Strengths of this study included comparison against the "gold standard" of standard care: community-based management of acute malnutrition at health clinics offering OTP and SFP in the same physical location, with RUSF offered to children with MAM instead of fortified blended flours. ComPAS was designed this way to capture the value added by simplifying and combining treatment. The reality is that many standard care programs are not able to provide RUSF for children with MAM, or the treatments for SAM and MAM are offered in separate physical locations. Another strength was the inclusion of 2 different contexts contributing to a combined dataset. The multi-country nature of the trial increases the generalizability of the results, with both rural and urban settings contributing data.

ComPAS faced several operational limitations. The contexts in Nairobi and Aweil East are very different, but the study sites were not large enough to be independently powered. Therefore, the analysis is only powered for combined multi-country estimates. Though our inclusion criteria included children up to 59 months, the majority were less than 24 months, so care should be taken in extrapolating the results to older or larger children. A non-inferiority margin of 10% was selected in consideration of previous program data from Aweil East and Nairobi. Actual proportions recovered are within a slimmer margin, with adjusted and unadjusted risk differences for both the per-protocol and intention-to-treat analyses within a 5%--6% margin ([Table 2](#pmed.1003192.t002){ref-type="table"}; [Fig 2](#pmed.1003192.g002){ref-type="fig"}). In Aweil East, access to 4 of the clinics during the rainy season (May to November) was limited. Two of these clinics implemented the combined protocol, and 2 of the clinics implemented the standard protocol. One of the clinics was so inaccessible that supplies could not be delivered for more than 3 months. In Nairobi, mothers were often unable to take time off work to bring their children for regular visits, and some children with medical complications were not admitted to inpatient care for the same reason. The health clinics in Kenya were affected by a national nurse's strike from June to November 2017, which resulted in brief clinic closures and reduced availability of nursing staff. A national presidential election in August 2017, followed by a repeat election in October 2017, contributed to an atmosphere of uncertainty and some instability in the areas of Nairobi where the study took place. Many children were not able to attend their scheduled visits for several weeks during each election period, while families traveled to their rural homes to vote. All the factors above contributed to high defaulting in both contexts, reflected similarly in both arms, and may have negatively affected average daily weight gains. We have no reason to suspect that treatment acceptability had any role in defaulting. High defaulting drove down the overall recovery rates in the intention-to-treat analyses, which did not meet Sphere standards \[[@pmed.1003192.ref040]\]. High defaulting also inflated the cost per child recovered. Defaulting did not impact our assessment of non-inferiority of recovery as the required number of participants completing treatment was met across clusters and arms.

The same underlying factors that drove high defaulting in both arms also contributed to frequent missed visits and longer lengths of stay. We do not attribute the longer lengths of stay to a difference in dosage protocol, as the lengths of stay were similar between arms. Where defaulting and missed visits are common, extending the period in treatment allows for more children to reach recovery. In our analyses, many children went on to recover after the 16-week cutoff for non-response ([S1 Fig](#pmed.1003192.s001){ref-type="supplementary-material"}; [S2 Fig](#pmed.1003192.s002){ref-type="supplementary-material"}).

The cost savings assessed in this trial were limited in scope. Though our method for assessing cost-effectiveness removed many of the research-specific costs \[[@pmed.1003192.ref034]\], it was not possible to fully separate research versus programming costs in the analysis, so the total cost per child is higher than in many program settings. The costs reflect the combined inputs of NGOs and ministries of health, both of which contributed to the treatment of children. Additionally, the settings of Nairobi, Kenya, and Aweil East, South Sudan, have unique cost implications that may not affect other programs, such as the high costs of rent in a capital city and the high logistics and security costs of operating a clinical trial in a conflict-affected context. Average costs in a non-research setting, although highly variable by context, are often around US\$200 per child recovered \[[@pmed.1003192.ref048],[@pmed.1003192.ref049]\].

There were large differences in costs between countries. It is important to note that costing results reflect the caseloads and characteristics of the sample at the country level, but the study is not statistically powered to make conclusions about differences in effectiveness. In South Sudan, there were 3 main reasons for cost savings in the combined protocol: (1) higher recovery and lower length of stay in the combined protocol arm ([S5 Table](#pmed.1003192.s011){ref-type="supplementary-material"}), (2) a higher burden of SAM (with a reduced dosage of RUTF compared to the standard protocol), and (3) an independent supply chain. In Kenya, the larger proportional burden of MAM to SAM cases ([S3 Table](#pmed.1003192.s009){ref-type="supplementary-material"}) and the presence of a centralized medical supply chain through the national government meant cost savings were not apparent. RUTF had a slightly higher price than RUSF (US\$0.33 versus US\$0.29 per sachet), which affected the cost of MAM treatment in the combined protocol.

Future studies should assess whether additional savings can be achieved from increased efficiencies throughout the larger system for managing acute malnutrition in operational settings. Further research is needed to assess cost-effectiveness in a scaled-up system treating SAM and MAM in 1 protocol with 1 food product across a variety of contexts. Operational studies could assess the impact of a simplified, combined protocol on SAM/MAM caseloads and resource use across multiple years. Potential cost savings may be possible through the prevention of SAM, with its associated medical complications and systematic medications. In the longer term, cost savings from increased efficiency and a reduction in SAM caseload may spread further upstream, addressing more of the MAM caseload. Earlier treatment of acute malnutrition is likely to result in fewer long-term implications, helping children to better survive and thrive.

Adoption of a simplified and combined protocol may simplify operations in resource-constrained settings. A combined protocol reduces the need to procure 2 separate products for SAM and MAM treatment, streamlines program logistics and staff training, and enables a more holistic continuum of care for children with acute malnutrition. A simplified protocol may also facilitate delivery of treatment by community health workers, to improve access and reduce defaulting, an important area of work that calls for research. In contexts where children are highly vulnerable to malnutrition---particularly in crises and chronically fragile situations---a combined protocol may offer some protection, enabling children to benefit from treatment before they deteriorate into life-threatening SAM. The optimal diagnostic criteria and dosage of therapeutic foods may differ by setting, and further research should explore these setting-specific issues and the operational and physiological impacts of expanding treatment of MAM \[[@pmed.1003192.ref017]\]. The potential benefits of a simplified protocol may be weighed against economic considerations including implications for the supply chain of ready-to-use foods, and the impact on caseload and cost when treatment is made more readily available to moderately malnourished children. Further research is also needed to assess the safety and effectiveness of a reduced dosage protocol in children with SAM and in older or larger children. Though our study did not find evidence of harm among any sub-groups, including those with SAM and older children, future studies could be powered to assess those populations specifically. Our findings are consistent with other studies that indicate that a reduced dosage for SAM does not lower recovery \[[@pmed.1003192.ref021],[@pmed.1003192.ref022],[@pmed.1003192.ref030],[@pmed.1003192.ref031]\], but research is needed to understand why a reduced dosage is effective and the contextual factors that affect recovery. Investigating the effects of context (e.g., differences between African and Asian settings, differences between food-insecure settings and food-secure settings, and the impact of seasonality) is a priority.

The reality is the current system fails to reach the majority of children who need treatment, and resources are already limited. If the global health community is to meet SDG nutrition targets, new approaches are urgently needed. This is particularly true with the emergence of SARS-CoV-2, which has further necessitated a consideration of simplified, easy-to-use, and cost-effective nutrition treatment approaches. The number of malnourished children may rise as a result of the pandemic due to economic and biological factors, and the ability of the health system to respond may be strained. Simplified protocols can be incorporated into an adapted approach that could be delivered by community health workers at home and that optimizes the use of ready-to-use foods. Further research should assess how simplified nutrition protocols can be part of the response to this need, optimizing existing resources to reach more children while maintaining a high level of clinical care for all sub-groups. Streamlined, cost-effective programs make a more persuasive case for future investment, and this in turn is more likely to result in public health impact at scale.
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Recovery rate in both ITT and per-protocol. In the ITT it barely meets the Sphere standard for the combined protocol. In the per protocol- it is substandard. While the authors note the reasons for defaulting, it is exceptionally low. it also make me question the acceptability of the programs overall.

The two contexts in the RCT are extremely different and this variation dies not come out in the summary statistics. While the study was powered to only produce a combined analysis, South Sudan is really quite different that then slums of Nairobi and the supplemental table 4 demonstrates those programming variations- for example length of stay. In terms of the cost effectiveness, I see this as significant limitation. However, the authors address the limitations in the discussion.

Reviewer \#2: Bailey et al present the results of a cluster randomized non-inferiority trial of a simplified, combine protocol for SAM and MAM compared to standard treatment. This is an important trial and addresses a subject of much discussion in the nutritional programming community. The authors describe this trail, which took place in Kenya and South Sudan with children enrolled in a total of 24 clinics. The authors find that the combined treatment for SAM and MAM is non-inferior to standard care concerning recovery. The authors also provide cost-effectiveness information.

There is no doubt that addressing this question adds to the literature. That being said, the article requires some aspects to be more clearly addressed by the authors.

1\) There is an extraordinarily high loss to follow up (defaulting). As the authors state, this occurs in both arms, but is alarming. As such, the results, it could be argued, a limited to statement such as \"among children remaining in the program, the two protocols were non-inferior.\" The differences between the ITT and PP analyses are such that this warrants a much larger discussion by the authors. Although balanced between arms, this is far above what would be acceptable in a program and limits what can be drawn from this trial.

2\) The randomization warrants further clarity. From what I understand, the 24 health centers were selected, and then randomized to one of two groups. Then, the statistician was blinded until the database was locked? This is all fine, but then the randomization is both neither complex and the study is open label. Shouldn\'t the analyses have been done under blind? Is that what the authors mean?

3\) Although not typical, and this is greatly debated, I\'m not entirely convinced about the power of this study given that the underlying assumptions for the ITT were very different than expected. It would be useful for the authors to comment a bit more on the analyses, provide additional information on lost to follow-up by cluster, and discuss further issues concerning the analyses themselves. This is also the case for the rationale for a cluster randomized trial, which is certainly warranted here, but doesn\'t come out clearly in the manuscript. Further to this, I would be more inclined to present the paper a bit more formally (was this a DSMB or not? It\'s unclear why Table 1 results are commented on? More details is needed in terms of the analyses

Minor comments

\* Some of the references are duplicated

\* The introduction could be updated to provide more recent and comprehensive information

\* Some of the definitions are unclear, median? Z-score?

\* The cost-effectiveness analysis is interesting, but it seems a bit less attention is paid to it in terms of framing this in a context of so many lost-to-follow up.

Reviewer \#3: The authors have reported the results of a recent, large non-inferiority cluster-RCT comparing the effectiveness of a combined protocol against standard care of ready to use therapeutic foods to treat sever and moderate acute malnutrition for 6-59 month old children in Kenya an South Sudan. They have found that the simplified combined protocol was non-inferior to standard protocol as defined by their primary outcomes of difference in proportion who experienced nutritional recovery. The results are convincing and important, which will likely have impact to change practice, given the large sample size, recruitment across both rural and urban settings, and the base case economic analyses show that the simplified protocol is also cheaper.

The manuscript is well-written, methodological sound in terms of recruitment methods, randomisation and analysis. I have very little critique and commend the authors on an impressive trial in a challenging environment. The recency of the trial also highlights a very important topic area of global significant with a large number of children suffering from acute malnutrition, in particular areas of Africa, leading to a high rate of morbidity of mortality. A simplified approach to nutrition supplementation may make it easier for clinics to operationalise and implement this approach in diverse settings. Future research should explore implementation research of the approach.

Overall I have very little critique of the paper. My only minor comments are:

Methods - description of the analysis: Generally, cluster RCT analyses are a bit more complex - outcomes at follow-up can be analysed either at aggregrate level cluster level of individual outcomes, with both cases adjusting for baseline covariates. If individual level outcomes are analysed at follow-up (which it seems like this study) - then the analysis should allow for clustering using a mixed regression or generalised estimation equations. see Donner A, Klar N. Design and analysis of cluster randomization trials in health research. Arnold, 2000. It would be helpful if the authors could describe in method the type of model and regression technique they utilised. Line 226 simply states \"regression analyses\" which is too generic here.

Methods - covariate adjustment - I see that the analyses have been adjusted for clustering. It\'s not clear from the methods section whether baseline adjustments to differences in children anthropometry were considered and adjusted. Given the unit of randomisation of a Cluster-RCT in a group, analyses will often adjust for baseline given repeated nature of the outcomes and individual differences within groups, but if the authors did not they should rationalise why not (i.e. expected differences between groups were expected to be minimal at baseline).

Methods - it would helpful to specify that the z-scores were based on the WHO reference standards for growth charts.

Results - subgroup analyses: Given there are two geographical groups: rural and urban - was there any thought given to a potential sub-group analyses in urban and rural localities (i.e. most mothers in Aweil East report no formal education where as mothers in Nairobi reported secondary level attainment).

Reviewer \#4: Compas trial, Bailey et al.

This is an important trial and ditto manuscript and the authors should be congratulated on the large piece work and efforts put in this. I was impressed by the numbers in both groups, the non-inferiority as well as the costs saved.

Introduction: one of the major things that are missing in the current rationale and introduction is in lines 84-87, page 4: \"Evidence indicates...recover (Refs) till \"but a study....dosage\". Since the other arguments to come up with a combined approach for MAM (without danger signs) and uncomplicated SAM make sense, the authors need to elaborate in the introduction what this \"evidence\" indicates. The 3 references mentioned (24, 25, 26) should be briefly discussed or put into context. Did the authors in the papers/studies that are referred to use (in-)direct calorimetry, metabolic demands (RQ) to estimate and measure energy expenditure and usage? Was this done in the pre- or post RUTF era and were the study participants MAM or SAM patients? Lastly, it is not clear at present \'why\' one would want to have a reduced dosage (line 87). Since all these arguments are underlying the study rationale, this needs more explanation to better put this trial into perspective.

Page 5, Participants:

Line 120: it would be good to know the % of children that were enrolled via active case finding and the % that were enrolled without. Do the authors feel this might have been a source of bias?

P6, line 139: please clarify of the PI did all data-analyses and data interpretation?

Same page, line 145: the section on study procedures is quite difficult to read and comprehend and it took me 3 times to understand the work-flow.

Based on what evidence are the recommendations regarding intake done (\"Combined protocol clinics....to 1 sachet RUTF/day (line 149)\".

Page 14: since this is underlying the main result, that there is no difference between the 2 protocols and hence non-inferiority; I would recommend stressing that there was no difference between the ITT analysis versus the PP analysis.

Page 19, last few sentences of the results sections; the \'exploratory analyses\' show that subgroups recovered similarly. This is (in addition to my previous comment) an important finding and can (should) be presented a bit more prominently than is currently done.

The discussion reads well and is to-the-point. It would be interesting to elaborate a bit more on your ideas (lines 391-394) on the \'future research\' you suggest. Although I think you are right here it would be good from an academic perspective to hear your thoughts were in the spectrum from MAM to complicated SAM the combined protocol might still work and were it might stop being effective (non-inferior) to have 1 combined protocol.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003192.r002
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27 May 2020

Dear Dr. Bailey,

Thank you very much for re-submitting your manuscript \"A simplified, combined protocol versus standard treatment for acute malnutrition in children 6-59 months (ComPAS trial): a cluster randomized controlled non-inferiority trial in Kenya and South Sudan\" (PMEDICINE-D-19-03592R1) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Jun 03 2020 11:59PM.

Sincerely,

Clare Stone, PhD

Managing Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

Please add the mean age (combined cohort or individual groups) around line 38, and breakdown by sex.

Please change to 0.03 at line 40, and we don\'t want 0.00 included at line 44

Please provide a call out to the CONSORT checklist in the methods section

Please remove \"TM\" at line 180

Is there additional access info for ref 22?

Please update ref 24

Comments from Reviewers:

Reviewer \#2: The authors have responded clearly to the comments and this revised version is much improved. All questions have been responded to and this is an important trial for the nutrition community.

Reviewer \#3: I have re-read the manuscript and the authors have addressed all the comments appropriately. I have no further comments to add.

Reviewer \#4: Dear Authors,

I am happy with the comments to my review.

Kind regards,

Wieger Voskuijl

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003192.r004
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9 Jun 2020

Dear Ms Bailey,

On behalf of my colleagues and the academic editor, Dr. James Tumwine, I am delighted to inform you that your manuscript entitled \"A simplified, combined protocol versus standard treatment for acute malnutrition in children 6-59 months (ComPAS trial): a cluster randomized controlled non-inferiority trial in Kenya and South Sudan\" (PMEDICINE-D-19-03592R2) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Clare Stone, PhD

Managing Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

[^1]: The authors have declared that no competing interests exist.
